2020 China International Biopharma4.0 Summit
Feb,13th-14th,2020 | Shanghai China
2020年2月13日-14日 | 中国上海
Overview of 2020CIBP Summit
Based on the transformation &upgrading and policy reform of China’s pharmaceutical industry, and theprevious successful experience of last session, China International Biopharma4.0 Summit(2020) will further deepen topics concerning the implementation of specific policies and regulations on the biological cell culture technology, protein characterization and optimization and ICH-Q series, and discuss more practical topics such as Pharma 4.0, the latest progress in technologies, future trends, digitization and intelligence of biopharma companies, CGMP quality management system from laboratories to plants, regulations on the use of SUS, optimization of cell culture technology, advanced experience of upstream and downstream biopharma technology, and outsourcing technology development IP. The summit will also provide an optimal platform for you to communicate with government officials, CMO, CRO, biopharma companies, pharmaceutical device providers, software and logistics solutions providers, industry leaders and experts on international projects.
Gathering of global giants
500+ Delegates from BioPharma Industry.
250+ Global Biopharma Delegates
30+ Famous Experts
Gathering of industrial pioneers
30+ Worldwide Biopharma Solution Providers
50+ Media Exposure
Feb. 13th -14th , 2020 | Shanghai, China
International Biopharma 4.0 Summit 2020
Introduction of some
This summit provides a platform for participating representativesto have high-level dialogues. The representatives reached a cooperation intention on long-term projects on the site through in-depth exchange with high-level management of all enterprises and effective interaction between upstream and downstream industrial chain, which lent a splendid color to the summit. Most representatives were satisfied with the summit and expressed their expectation on the next session.

Dr.Jason Li

Trinomab Biotech Co. Ltd.

Jianfeng Gao

Sr.Director QA
Innovent Biologics

Dr. Hui Feng

Executive Director / COO
Junshi Biosciences

Ranjan Chakrabarti, Ph.D.

Vice President - Global Biologics
United States Pharmacopeial Convention

Xun Liu

Jiangsu Hengrui Medicine Co.,Ltd

Yinrui Jiang

Head of Oncology,China
Bristol-Myers Squibb

Jimmy Li

Vice President
WuXi Biologics

Jizu Yi

Vice President of CMC Process
Wuhan YZY Biopharma Co. Ltd

Dr. Joe Zhou

President/Principal Scientist
Genor Biopharma Co.,Ltd

Cuihua Liu

Vice President, Analysis and formulation research
Bio-Thera Solutions, Ltd.

Lawrence Yap

CMC Director
Takeda Pharmaceutical

Prof. Xianbao Zhan

GI Oncology Expert
Changhai Hospital

Uros Urleb

Global Head Technical Development Biosimilars

Zhiwei Song

Senior Scientist
Singapore A*STAR Biotechnology Institute




Borscon Group